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Aim: Abdominal aortic aneurysm (AAA) is a common vascular degenerative disease. AAA wall contains inflammatory cells
that produce matrix metalloproteinases (MMPs) that probably contribute to elastolysis and remodeling of the aneurysm.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to reduce the expression of
various molecules (including MMPs) independently of their cholesterol-lowering effect. The aims of this study are to
investigate whether statins could modulate the biology of AAA wall and have a potential therapeutic value against AAAs.
Methods: We performed immunohistochemical analysis, evaluated MMP-9 production in the aortic wall from patients
with infrarenal AAA (n  10) and control patients with aortoiliac occlusive disease (n  8), and examined the effect of
cerivastatin on MMP-9 production in the AAA wall with organ culture.
Results: Neutrophils and macrophages were the cellular sources of MMP-9 in the AAA wall. The tissue concentrations of
both total and active MMP-9 were significantly higher in tissues from AAA walls than in control aortic walls. Cerivastatin
(0.001 to 0.1 mol/L) significantly reduced the tissue levels of both total and active MMP-9 in a concentration-
dependent manner (P < .001), and the production of tissue inhibitor of MMP-1 was unaffected. Cerivastatin neither
reduced the number of infiltrating neutrophils and macrophages nor enhanced apoptosis of those cells, as evaluated with
terminal transferase-mediated deoxyurisine triphosphate nick end labeling.
Conclusion: These results suggest that cerivastatin can directly modulate the biology of the AAA wall and suppress
MMP-9 production in the AAA wall by inhibiting the activation of neutrophils and macrophages, indicating that statin
therapy could be useful for the prevention or treatment of AAA. (J Vasc Surg 2002;36:158-63.)
Abdominal aortic aneurysm (AAA) is a potentially fatal
disorder that affects 2% to 9% of the population over 65 years
of age.l,2 Although elective surgical repair or endovascular
stent grafting is an effective approach to avoid death from
ruptured AAA, there is a conspicuous absence of alternative
noninvasive therapeutic strategies for this disease.3
Because aortic aneurysms in humans are characterized
by destructive remodeling of the aortic wall, recent investiga-
tions have emphasized the mechanism of degradation of ma-
trix proteins.4,5 Several studies have shown that matrix metal-
loproteinases (MMPs), including MMP-2, MMP-9, and
MMP-12, contribute to the formation and development of
AAAs.6-8 MMP-9 has attracted particular interest because it is
the most abundant MMP in human AAA tissues7 and because
plasma MMP-9 levels are elevated in patients with AAA.9
MMP-9 expression also is correlated with an increase in AAA
diameter.10 Furthermore, targeted disruption of the MMP-9
gene suppresses the development of experimental AAAs.11
These observations have led to the speculation that MMP-9
might be essential for the development of AAAs and thus
may be a possible key target for pharmacotherapy.3
The cholesterol-lowering drugs known as 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins)
have been shown to suppress the in vitro expression of
various inflammatory molecules, including MMPs.l2-16
Therefore, we hypothesized that statins may have an inhib-
itory effect on MMP-9 production in human AAAs and
thus may have a potential therapeutic value for this disease.
To address this hypothesis, we performed an immunohis-
tochemical analysis of MMP-9, investigated the tissue con-
centration of MMP-9 in aortas from patients with AAA and
control patients, and assessed the effect of cerivastatin on
MMP-9 production in AAA tissue with organ culture.
METHODS
Subjects. Ten patients with infrarenal AAA and eight
control patients with aortoiliac occlusive disease were en-
rolled in this study at Tokyo Women’s Medical University
Hospital (Table). None of the patients were given choles-
terol-lowering therapy before surgery. Aortic aneurysm
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wall specimens were obtained from patients with AAA, and
control aortic specimens were collected from patients with
aortoiliac occlusive disease when elective surgery was per-
formed. After the specimens were harvested, each one was
immediately placed into 4% paraformaldehyde for immu-
nohistochemical analysis or into phosphate-buffered saline
solution (pH 7.2) for organ culture experiments. This
study was approved by the human ethics committee of our
institute, and all subjects gave written informed consent.
Immunohistochemical assays. We performed hema-
toxylin and eosin staining to determine overall architecture.
Immunohistochemistry was performed with a peroxidase-
labeled streptoavidin-biotin (Dako, Kyoto, Japan). The
antibodies that were used included mouse monoclonal
antibodies against human smooth muscle -actin antibody
(1A4, Dako), human CD68 (Dako), human CD45RO
(Dako), and human MMP-9 (Fuji Chemical Ltd, Tokyo,
Japan). The investigators performing this histologic evalu-
ation were blinded to the clinical data.
Organ culture of aortic wall. To assess the possible
therapeutic value of statins for AAA, we examined the effect
of cerivastatin on MMP-9 and tissue inhibitor of MMP-1
(TIMP-1) in aortic wall specimens from the patients with
AAA. Each specimen was cut into several pieces and was
cultured with culture medium for vascular smooth muscle
cells (HuMedia-SG2, Kurabou, Osaka, Japan) in an atmo-
sphere of 95% O2/5% CO2 at 37°C for 48 hours as de-
scribed previously17 with various concentrations of cerivas-
tatin (0.001 to 0.1 mol/L) or vehicle. For reversal
experiments against cerivastatin effect on MMP-9 production,
mevalonate (100 mol/L, Sigma, Tokyo, Japan), farnesyl
pyrophosphate (10 mol/L, Sigma), or geranylgeranyl pyro-
phosphate (10mol/L, Sigma) was added. The medium was
changed every 12 hours. After 48 hours, the tissue concentra-
tions of MMP-9 and TIMP-1 were determined.
Evaluation of tissue concentrations of matrix
metalloproteinase–9 and tissue inhibitor of matrix
metalloproteinase–1
The tissue levels of total MMP-9 and TIMP-1 were
examined with enzyme-linked immunosorbent assays (Fuji
Yakuhin Co Ltd) with antibodies against human MMP-9
and human TIMP-1. Active MMP-9 was detected through
prodetection enzyme and the subsequent cleavage of its
substrate with Biotrak MMP-9 activity assay system (Am-
ersham, Piscataway, NJ).
In situ detection of apoptotic cells. The terminal
transferase-mediated deoxyurisine triphosphate nick end
labeling (TUNEL) method was used to detect apoptotic
cells in deparaffinized 4-m thick sections with an Ap-
opTag in situ apoptosis detection kit (Oncor Inc, Gaithers-
burg, Md) according to the supplier’s instructions. Sections
were lightly counterstained with hematoxylin. Negative
controls included omission of terminal deoxynucleotidyl
transferase from the labeling mixture.
Apoptotic index. Four sections within the part of the
aorta showing the maximum dilatation were selected, and
four fields per section were examined at a 400-fold magni-
fication. Two independent investigators counted TUNEL-
positive cells, and their results were averaged. Then, the
apoptotic index was calculated with the following formula:
100  (number of TUNEL-positive cell nuclei per field/
total number of cell nuclei per field).
Statistical analysis. Analyses were performed with
SAS System 8e software (SAS Institute Inc, Cary, NC).
Results are presented as the mean  standard deviation.
The normality of the distribution of data was evaluated with
the Shapiro-Wilks one-sample test, and the F test was used
to assess the homogeneity of variance. Student t test was
used for the comparison of continuous data. Simple linear
regression model was used to perform the trend test. One-
way analysis of variance was used to test for significant
differences between the groups, and Dunnett multiple
comparison method was applied when appropriate. A two-
tailed P value of less than .05 was considered to indicate
statistical significance.
RESULTS
Immunohistochemical analysis of abdominal aortic
aneurysm tissues. The AAA wall contained many inflam-
matory cells, such as T cells, macrophages, mast cells, and
neutrophils. Staining for MMP-9 was positive in the neu-
Profile of subjects
Infrarenal
AAA
(n  10)
Aortoiliac
occlusive disease
(n  8) P value
Age (y) 64.8  4.2 68.9  5.1 NS
Male gender 9/10 (90.0%) 7/8 (87.5%) NS
Maximum diameter (cm) 5.8  0.9 – –
Systolic BP (mm Hg) 132.4  12.7 145.1  19.2 NS
Diastolic BP (mm Hg) 78.8  6.1 80.4  8.7 NS
TC (mg/dL) 222.2  23.4 228.8  19.0 NS
HDLC (mg/dL) 44.5  6.9 45.5  7.2 NS
LDLC (mg/dL) 137.1  15.8 133.0  10.9 NS
TG (mg/dL) 118.8  31.5 130.3  31.8 NS
BP, Blood pressure; TC, total cholesterol; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; TG, triglyceride; NS, not
significant.
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trophils and macrophages (Fig l), indicating that these cells
were a source of MMP-9 in the AAA wall. Although
smooth muscle cells also have been reported to produce
MMPs, smooth muscle cells with positive staining for
MMP-9 could not be detected in AAA tissue in this study.
Aortic tissue production of matrix metalloproteinase–
9. Next, we investigated tissue concentrations of total and
active MMP-9 in the AAA wall. Both total and active
MMP-9 were significantly higher in the aortas of patients
with AAA than in those of control patients (Fig 2; P .05).
Effect of cerivastatin on matrix metalloproteinase–9
production. We tested whether cerivastatin could influ-
ence the production of MMPs in AAA tissues. Addition of
cerivastatin (0.001 to 0.1 mol/L) to organ cultures sig-
nificantly reduced the tissue levels of both total and active
MMP-9 in a concentration-dependent manner (P  .001;
Fig 3). Suppression of both total and active MMP-9 levels
with cerivastatin was reversed after the addition of meval-
onate, farnesyl pyrophosphate, or geranylgeranyl pyro-
phosphate, suggesting that it occurred through blocking of
the mevalonate pathway (Fig 4). TIMP-1 production was
not affected by cerivastatin (data not shown).
Effect of cerivastatin on apoptosis in abdominal
aortic aneurysms. The immunohistochemical findings
suggested that the source of MMP-9 in AAA lesions was
neutrophils and macrophages. There are two possible
mechanisms for modulating the secretion of MMP-9 with
these cells: one is biologic regulation of MMP-9 produc-
tion and the other is a decrease in the number of infiltrating
cells. Accordingly, we examined the effect of cerivastatin on
the total number of these cells and on apoptosis in organ
culture experiments. We found that cerivastatin neither re-
duced the number of neutrophils and macrophages nor
enhanced their apoptosis according to the results of
TUNEL staining (data not shown).
DISCUSSION
Aneurysmal degeneration of the aorta involves destruc-
tive remodeling of the aortic wall matrix that is associated
with chronic inflammation and local overproduction of
MMPs. This study showed two major findings. First,
MMP-9 production was upregulated in the AAA wall.
Several other studies have shown abundant expression of
MMP-9,7 a high serum level of MMP-9,9 and suppression
of the development of experimental AAA with MMP-9
gene disruption.11 Taking our results together with these
previous reports, MMP-9 seems to play a pivotal role in the
pathogenesis and development of AAA. Our immunohis-
tochemical study revealed that inflammatory cells, such as
neutrophils and macrophages, were a cellular source of
MMP-9 in the AAA wall (Fig 1). In atherosclerotic lesions,
the importance of the activation of these cells and subse-
quent MMP secretion has been emphasized. Macrophages
are reported to be activated and to show upregulation of
MMP-9 expression in atherosclerotic plaques, which might
play a critical role in plaque instability.18,19 Also in AAAs,
infiltrating macrophages were shown to be the principal
source of MMP-9 with studies with in situ hybridization.7
Fig 1. Immunohistochemical analysis. A, AAA tissue contains numerous inflammatory cells and MMP-9-positive cells
(magnification, 20). B, CD45RO staining for T lymphocytes (magnification, 20). C, CD68 staining for macro-
phages (magnification, 20). MMP-9 is produced by macrophages in atheromatous plaque (D), by neutrophils in vasa
vasorum (E), and by neutrophils infiltrating aortic tissue (F; magnification, 100).
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Furthermore, recent studies have indicated that neutrophil
activation plays a central role in acute coronary syndrome
associated with atherosclerotic plaque.20 Although several
reports have shown that MMP-9 is not necessary for neu-
trophil migration,21,22 this study confirmed that neutro-
phils secrete MMP-9 in AAA tissues. Because how and
where these cells are activated is still unknown, further
investigations will be necessary to elucidate the functional
role of neutrophils in the pathogenesis of AAA.
Second, we showed that incubation with a statin could
suppress MMP-9 production in AAA tissues. Statins de-
crease the conversion of 3-hydroxy-3-methylglutaryl coen-
zyme A into mevalonate, a precursor of endogenous cho-
lesterol. Lipid-lowering therapy has been shown to have a
clinical value for the prevention of cardiovascular dis-
ease.23-25 However, recent reports have shown that statins
not only have a lipid-lowering effect but also possess direct
vascular effects that involve modulating the expression of
various molecules in the arterial wall.12-16 This study
showed that cerivastatin has an inhibitory effect on the
production of MMP-9 in cultured human AAA wall. Such
inhibition of MMP-9 suggests a potential therapeutic value
of statins for patients with AAA. In this study, enzyme-
linked immunosorbent assays were performed to measure
MMP-9 levels. We could not do following Western blot or
enzyme zymography because of the limitation of human
Fig 2. Tissue levels of total and active MMP-9 in control aortas and AAA tissues. Both total and active MMP-9 levels
were significantly higher in AAA tissues than in control aortas (P  .05).
Fig 3. Cerivastatin significantly reduced levels of both total and active MMP-9 in concentration-dependent manner in
organ cultures. P value of trend test, .001.
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sample quantities. MMP-9 is secreted by most cells as a
complex with TIMP-1,26 so an expectation that TIMP-1
could also be affected by cerivastatin might be reasonable.
However, we found that the TIMP-1 concentration in
AAA tissues was not changed by incubation with cerivasta-
tin (data not shown). We also investigated whether the
decrease of MMP-9 in AAA tissues was caused by a reduc-
tion in the number of macrophages and neutrophils or by
inhibition of its production. Because cerivastatin treatment
did not affect the number of these cells in AAA tissues or
their apoptosis rate (data not shown), cerivastatin seem-
ingly directly inhibited the activation of neutrophils and
macrophages in AAA tissues.
This study was aimed not to show a clinical use of
cerivastatin but to address a potential therapeutic value of
statins. The concentration used in our organ culture exper-
iments was close to the peak plasma concentration achieved
in humans, indicating that the effects on AAAs shown in
this study might be reproduced in the clinical setting.
CONCLUSION
This study showed that cerivastatin suppresses the pro-
duction of MMP-9, which contributes to elastolysis and the
remodeling of AAAs, suggesting that cerivastatin might
have a potential clinical value for use in preventing this
disease.
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